- Our news -

 

atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

 

perception neuroscience presents results from phase 2b trial of pcn-101 at the ascp 2023 annual meeting

 

Perception Neurosciences Announces Additional Analyses from the Phase 2a Trial of PCN-101 (R-ketamine) at the ASCP 2023 Annual Meeting

 

PERCEPTION NEUROSCIENCE ANNOUNCES FIRST DOSING OF SUBJECTS IN THE PCN-101 IV-TO-SUBCUTANEOUS BRIDGING STUDY

 

Perception Neuroscience Announces Appointments of Maju Mathews, MD, as Chief Medical Officer and Cedric Burg, PhD as Senior Vice President, Clinical Operations

 

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

 

Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders

 

Perception Neuroscience announced positive data from its first Phase 1 clinical study demonstrating the safety and tolerability of PCN-101 (R-ketamine).

 
ATAI logo.jpg

Terence Kelly appointed CEO of ATAI platform company Perception Neuroscience

 
QC logo larger.png

ATAI Life Sciences acquires majority stake in Perception Neuroscience to develop arketamine therapy for neuropsychiatric diseases

 

- Other news -

 
terry x florian.png

Are Investors Ready To Change Their Minds About Psychedelic Drugs?

Yet as Dr. Terence Kelly, CEO of Perception Neuroscience, noted, the regulatory authorities are very familiar with psychedelic substances and tend to be cooperative regarding their research.